The following video is part of our "Motley Fool Conversations" series, in which analyst Jim Mueller and analyst Jason Moser discuss topics around the investing world.

Dendreon (Nasdaq: DNDN) has had a volatile history as a stock as it developed and then brought to market its prostate cancer drug, Provenge. Today, Motley Fool Stock Advisor analysts Jim Mueller and Jason Moser discuss why today might finally be the time to invest in this biotech company.

Jason Moser has no positions in the stocks mentioned above. Jim Mueller owns shares of Johnson & Johnson and has options on Dendreon. The Motley Fool owns shares of Dendreon and Johnson & Johnson. Motley Fool newsletter services recommend Johnson & Johnson. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.